ApprovalTrail

Approval · Notice of Compliance 36033 · 2025

JAMP-ZOLMITRIPTAN: Notice of Compliance 36033

Issued September 19, 2025

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
36033
Date
September 19, 2025
Company
JAMP Pharma CorporationBoucherville, Quebec, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to an Abbreviated New Drug Submission (SANDS), supplement
Submission class
Admin
Reason
Administrative: Update to labelling (to match Licensor)
Canadian reference product
ZOMIG (Astrazeneca Canada Inc)

Products in this notice

BrandDINStatus today
JAMP-ZOLMITRIPTANNot yet assigned—

Medicinal ingredients